Use of the Prostate-Specific Antigen Test Among Men Aged 75 Years or Older in the United States: 2006 Behavioral Risk Factor Surveillance System

Preventing Chronic Disease

Volumn 7, Issue 4, 2010, Pages

  Li, Jun ^a   Zhao, Guixiang ^a   Pollack, Lori ^a   Smith, Judith Lee ^a   Joseph, Djenaba ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; HEALTH CARE DELIVERY; HEALTH INSURANCE; HUMAN; INCIDENCE; MALE; MASS SCREENING; PATIENT ATTITUDE; PROSTATE TUMOR; SOCIAL SUPPORT; STATISTICS; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; HEALTH SERVICES ACCESSIBILITY; HUMANS; INCIDENCE; INSURANCE, HEALTH; MALE; MASS SCREENING; PATIENT ACCEPTANCE OF HEALTH CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOCIAL SUPPORT; UNITED STATES;

EID: 77957081746     PISSN: 15451151     EISSN: 21665435     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. US Cancer Statistics Working Group. United States cancer statistics: 1999-2005 incidence and mortality Web-based report. Atlanta (GA): Centers for Disease Control and Prevention and National Cancer Institute; 2009.
2. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002;29(1):173-81.
3. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95(12):868-78.
4. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148(6):435-48.
5. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149(3):185-91.
6. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? JAMA 2003;289(11):1414-20.
7. Jerant AF, Franks P, Jackson JE, Doescher MP. Age-related disparities in cancer screening: analysis of 2001 Behavioral Risk Factor Surveillance System data. Ann Fam Med 2004;2(5):481-7.
8. Smith RA, Cokkinides V, Eyre HJ. Cancer screening in the United States, 2007: a review of current guidelines, practices, and prospects. CA Cancer J Clin 2007;57(2):90-104.
9. Scales CD Jr, Antonelli J, Curtis LH, Schulman KA, Moul JW. Prostate-specific antigen screening among young men in the United States. Cancer 2008;113(6):1315-23.
10. Lu-Yao G, Stukel TA, Yao SL. Prostate-specific antigen screening in elderly men. J Natl Cancer Inst 2003;95(23):1792-7.
11. Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. JAMA 2006;296(19):2336-42.
12. Hudson SV, Ohman-Strickland P, Ferrante JM, Lu-Yao G, Orzano AJ, Crabtree BF. Prostate-specific antigen testing among the elderly in community-based family medicine practices. J Am Board Fam Med 2009;22(3):257-65.
13. Barger SD, Donoho CJ, Wayment HA. The relative contributions of race/ethnicity, socioeconomic status, health, and social relationships to life satisfaction in the United States. Qual Life Res 2009;18(2):179-89.
14. Albertsen PC. PSA testing: public policy or private penchant? JAMA 2006;296(19):2371-3.
15. McNaughton Collins M, Stafford RS, Barry MJ. Age-specific patterns of prostate-specific antigen testing among primary care physician visits. J Fam Pract 2000;49(2):169-72.
16. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137(11):917-29.
17. Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis 2007;4(4). http://www.cdc.gov/pcd/issues/2007/Oct/06_0051.htm. Accessed February 9, 2010.
18. Scales CD Jr, Curtis LH, Norris RD, Schulman KA, Albala DM, Moul JW. Prostate specific antigen testing in men older than 75 years in the United States. J Urol 2006;176(2):511-4.
19. Steele CB, Miller DS, Maylahn C, Uhler RJ, Baker CT. Knowledge, attitudes, and screening practices among older men regarding prostate cancer. Am J Public Health 2000;90(10):1595-600.
20. McDavid K, Melnik TA, Derderian H. Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997. Prev Med 2000;31(3):195-202.
21. American College of Physicians. Screening for prostate cancer. Ann Intern Med 1997;126(6):480-4.
22. Ross LE, Coates RJ, Breen N, Uhler RJ, Potosky AL, Blackman D. Prostate-specific antigen test use reported in the 2000 National Health Interview Survey. Prev Med 2004;38(6):732-44.